The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1508
Minimed 670G: A Hybrid Closed-Loop Insulin Delivery System
The full article is available to subscribers Subscriber Login   

The FDA has approved the Minimed 670G (Medtronic), a hybrid closed-loop insulin delivery system for use in patients ≥14 years old with type 1 diabetes. The system uses an algorithm to automatically adjust basal insulin doses based on readings from a continuous glucose monitor (CGM). It fully automates basal insulin delivery in "auto" mode, but is considered a "hybrid" system (not a true "artificial pancreas") because it requires some action by the patient. The 670G system is expected to become available in Spring 2017.

RELATED DEVICES — The Minimed 630G system was approved in August 2016 and is currently available; it has a less accurate CGM sensor than the 670G and does not automatically adjust insulin doses based on CGM readings. The 670G, 630G, and the earlier Minimed 530G all have an automatic suspend feature that alerts the patient and stops insulin ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Minimed 670G: A Hybrid Closed-Loop Insulin Delivery System
Article code: 1508a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian